Is IONS a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Owned commercial launches, with revenue (ttm) at ~$874M; 2025 revenue ~$944M. The bear case rests on ionis still operates at a loss, with 2026 non-GAAP operating loss guidance in the range of roughly $425 million to $475 million, and a trailing-twelve-month net loss of about $565 million, so profitability remains unproven. Analysts covering it are spread from $54.00 to $105.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Ionis still operates at a loss, with 2026 non-GAAP operating loss guidance in the range of roughly $425 million to $475 million, and a trailing-twelve-month net loss of about $565 million, so profitability remains unproven. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $54.00, +25.8% from the $42.94 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Owned commercial launches. Ionis is shifting from a royalty-and-partnership model to selling its own drugs, led by Tryngolza and Dawnzera launched in 2025. The most optimistic analyst target on IONS is $105.00, +144.5% from the $42.94 price. That figure is only reachable if this thesis works close to its best case.

Ionis still operates at a loss, with 2026 non-GAAP operating loss guidance in the range of roughly $425 million to $475 million, and a trailing-twelve-month net loss of about $565 million, so profitability remains unproven. The share price has already fallen about 46% in 2026, showing how sharply sentiment can turn on clinical news. Its value is heavily tied to a handful of launches and regulatory decisions, meaning a disappointing Phase 3 readout, a delayed or rejected FDA filing, or a slow launch could sharply pressure the stock. The Tryngolza sHTG label carries warnings for hypersensitivity reactions and liver enzyme abnormalities, which could shape uptake. It competes directly with Alnylam's RNA-interference platform in overlapping rare and cardiovascular diseases, and some of its biggest products are shared with partners like Biogen and AstraZeneca who control much of the commercial reach. Pricing pressure, safety findings, and patent or competitive erosion on older drugs add further uncertainty. As a biotech, the shares can be highly volatile around clinical and regulatory events. The most pessimistic published target is $54.00, +25.8% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Ionis Pharmaceuticals is a California-based biotechnology company that invented and commercialized antisense technology, a way to design short strands of nucleic acid that silence

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Owned commercial launches) stalling in the reported numbers rather than in the narrative, the risk above (ionis still operates at a loss, with 2026 non-GAAP operating loss guidance in the range of roughly $425 million to $475 million, and a trailing-twelve-month net loss of about $565 million, so profitability remains unproven) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Ionis is a commercial-stage biotechnology company that pioneered antisense technology, designing RNA-targeted drugs that silence or modify disease-causing proteins. It markets several medicines and develops a broad pipeline across rare, neurological, and cardiometabolic diseases.

Not yet on a sustained basis. Revenue is growing quickly, but the company still guides to a non-GAAP operating loss for 2026 (roughly $425 million to $475 million) as it invests in launches and trials. Profitability depends on its owned products scaling up. Over the twelve months to June 2026 it lost about $565 million on ~$874 million of revenue.

Its first wholly owned launches are Tryngolza (olezarsen) for familial chylomicronemia syndrome and Dawnzera for hereditary angioedema. It also has partnered products including Spinraza, Wainua, Qalsody, Tegsedi, and Waylivra.